NASDAQ: BNBXBnb Plus Corp Stock
$2.64+0.04 (+1.54%)
Updated Dec 1, 2025
BNBX Price
$2.64
Fair Value Price
N/A
Market Cap
$3.41M
52 Week Low
$2.13
52 Week High
$190.80
P/E
-0.01x
P/B
0.47x
P/S
0.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.30M
Earnings
-$13.19M
Gross Margin
39.6%
Operating Margin
-399.87%
Profit Margin
-2,047.4%
Debt to Equity
0.41
Operating Cash Flow
-$13M
Beta
0.68
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BNBX Overview
BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BNBX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
BNBX
Ranked#48 of 48
Ranked#48 of 48
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $17.35 | A | |
| $728.97 | A | |
| $224.14 | B |
Be the first to know about important BNBX news, forecast changes, insider trades & much more!
BNBX News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BNBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BNBX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BNBX is good value based on its book value relative to its share price (0.47x), compared to the US Diagnostics & Research industry average (4.5x)
P/B vs Industry Valuation
BNBX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BNBX due diligence checks available for Premium users.
Valuation
BNBX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
23.05x
Market
45.08x
BNBX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.47x
Industry
4.5x
BNBX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BNBX's financial health
Profit margin
Revenue
$304.4k
Net Income
-$3.9M
Profit Margin
-6,388.3%
BNBX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BNBX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.9M
Liabilities
$2.9M
Debt to equity
0.41
BNBX's short-term assets ($5.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BNBX's short-term assets ($5.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BNBX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BNBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.8M
Investing
$10.1k
Financing
$723.1k
BNBX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BNBX vs Diagnostic & Research Stocks
Bnb Plus Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.